Novel molecular targeted therapies for refractory thyroid cancer. [electronic resource]
Producer: 20120813Description: 736-45 p. digitalISSN:- 1097-0347
- Angiogenesis Inhibitors -- therapeutic use
- Anilides -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Axitinib
- Benzamides
- Benzenesulfonates -- therapeutic use
- Benzoquinones -- therapeutic use
- Bibenzyls -- therapeutic use
- Boronic Acids -- therapeutic use
- Bortezomib
- Depsipeptides -- therapeutic use
- ErbB Receptors -- antagonists & inhibitors
- Gefitinib
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Histone Deacetylase Inhibitors -- therapeutic use
- Humans
- Hydroxamic Acids -- therapeutic use
- Imatinib Mesylate
- Imidazoles -- therapeutic use
- Indazoles -- therapeutic use
- Indoles -- therapeutic use
- Lactams, Macrocyclic -- therapeutic use
- Lenalidomide
- Niacinamide -- analogs & derivatives
- Oligonucleotides
- Phenylurea Compounds -- therapeutic use
- Piperazines -- therapeutic use
- Piperidines -- therapeutic use
- Protein Kinase Inhibitors -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins c-kit -- antagonists & inhibitors
- Pyrazines -- therapeutic use
- Pyridines -- therapeutic use
- Pyrimidines -- therapeutic use
- Pyrroles -- therapeutic use
- Quinazolines -- therapeutic use
- Quinolines -- therapeutic use
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Sorafenib
- Sulfonamides -- therapeutic use
- Sunitinib
- Thalidomide -- analogs & derivatives
- Thyroid Neoplasms -- drug therapy
- Valproic Acid -- therapeutic use
- Vorinostat
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.